About Me
Engineering the Future of Medicine.
I work at the interface of biomaterials, gene delivery, and systems immunology to design next-generation genetic medicines and immune-engineering platforms.
Selected Publications
Google Scholar - 0 citationsNature Chemical Engineering2026
- A reversible post-assembly crosslinking strategy enhances LNP-mediated mRNA delivery while preserving intracellular release, enabling improved endosomal escape, sustained in vivo expression, and robust immune and antitumor responses.
Materials Today2026
- Screening 1,944 formulations identified LipidBrick® LNPs that outperform the clinical benchmark ALC-0315, producing stronger antigen-specific T-cell responses while maintaining low cytotoxicity.
Nature Communications2025
- An mRNA LNP-incorporated microgel matrix recruits immune cells, supports antigen expression and presentation, and elicits potent antitumor efficacy with a single administration.
Science Advances2025
- A multistep in vivo screening platform identified LNPs that preferentially target the spleen and deliver CRISPR-Cas9 ribonucleoproteins directly to T cells, enabling efficient gene editing without ex vivo manipulation.
Nature Biomedical Engineering2024
- An LNP screening strategy optimized helper lipid identity and component ratios to enhance dendritic cell delivery of tumour-antigen-encoding mRNA and improve immune activation toward stronger antitumour responses.
Nature Chemical Engineering2024
- Matching cell culture viscosity to that of biological fluids substantially improves transfection efficiency across multiple gene delivery platforms and cell types.
Biomaterials2024
- A multi-step screening strategy identified pDNA LNP formulations for intraduodenal delivery and non-viral gene editing in mouse liver, reducing PCSK9 and ANGPTL3 to lower LDL cholesterol.
Nature Communications2022
- A multi-step platform identified optimized plasmid DNA LNPs for liver-targeted delivery and prolonged transgene expression, addressing a major gap in systematic pDNA LNP design.
Nano Letters2021
- Size-controlled pDNA/PEI particles improved lentiviral vector production, with an optimal particle size of 400-500 nm linked to enhanced cellular uptake and transfection efficiency.
Journal of Controlled Release2020
- Albumin-biomineralized nanoparticles co-delivering a photosensitizer and immunoadjuvant were engineered to couple tumor ablation with immune activation for melanoma therapy.